Related Tags >> FDA GlaxoSmithKline Mergers and Acquisitions Cephalon

Valeant Pharmaceuticals News

Most Popular Valeant Pharmaceuticals Story

Hungry Valeant snags Eyetech in ongoing buyout spree

February 13, 2012 — 9:26am ET | By John Carroll

Valeant Pharmaceuticals today continued its restless buyout spree, snapping up Eyetech, a small FL-based company that sells the anti-VEGF pioneer Macugen in the U.S. And while Valeant ($VRX) didn't Read more...

Valeant Pharmaceuticals Press Releases

Latest Headlines

Hungry Valeant snags Eyetech in ongoing buyout spree
February 13, 2012
Valeant Pharma's $345M buyout signals opportunity for biotechs
July 15, 2011
FDA provides conditional OK for GSK/Valeant's epilepsy drug
June 13, 2011
Valeant CEO scanning biopharma horizon for fresh targets
May 4, 2011
Valeant offers a stick, a carrot and a May 12 deadline to Cephalon investors
April 21, 2011
Valeant may sweeten Cephalon bid
April 11, 2011
Valeant faces a fight after Cephalon rejects offer
April 6, 2011
Fund sues Cephalon over Valeant bid
April 1, 2011
Valeant vows to restructure Cephalon as it moves in for the kill
March 31, 2011
Cephalon shares rocket up after Valeant makes $5.7B hostile bid
March 30, 2011
FDA rejects a new epilepsy drug from Valeant, GSK
December 2, 2010
Waksal inks pair of hepatitis C pacts for his start-up
November 2, 2010
Biovail-Valeant combo will cost 25% of all jobs
September 7, 2010
FDA panel backs new epilepsy drug from GSK, Valeant
August 12, 2010
FDA staffers weighs risks, rewards of new epilepsy drug
August 9, 2010
Biovail, Valeant Pharma strike merger deal
June 21, 2010
Valeant to buy orphan drug developer Aton for $318M
May 3, 2010
Valeant Pharma eyes NC office
April 8, 2010
Valeant pays $115M for Dow Pharma drug rights
September 29, 2009
Key Valeant drug fails mid-stage pain trial
August 24, 2009

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events